Biogen partners with Cambridge‑based TRIMTECH on protein degraders for neurodegenerative disease

Biogen and TRIMTECH Therapeutics have entered a collaboration to discover and develop small‑molecule protein degraders aimed at neurodegenerative disorders. Under the agreement TRIMTECH can receive as much as $32 million in upfront and research milestone payments, with the total upside reaching $411 million plus royalties if milestones are met. Biogen will obtain an option to secure an exclusive worldwide licence and will assume responsibility for later development and commercialization. TRIMTECH CEO Nicki Thompson described the deal as a significant validation of the company’s platform.

The partnership gives TRIMTECH a potential multi‑hundred‑million‑dollar revenue stream while allowing Biogen to add a novel targeted‑protein‑degradation approach to its neuro‑degeneration pipeline. Investors should watch for milestone payments that could materially affect TRIMTECH’s cash position and for any future licensing or royalty receipts.

  • 1TRIMTECH may receive up to $32 million in upfront and research milestone payments.
  • 2The total possible consideration under the deal is $411 million, plus royalties on future sales.
  • 3Biogen holds an option to obtain an exclusive global licence to the degraders and will lead later development and commercialization.
  • 4TRIMTECH CEO Nicki Thompson said the collaboration is a major milestone for the company.

Sources